No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects


Yonal O., EREN F., YILMAZ Y., ATUĞ Ö., Over H. H.

TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.25, sa.6, ss.639-643, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 6
  • Basım Tarihi: 2014
  • Doi Numarası: 10.5152/tjg.2014.6568
  • Dergi Adı: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.639-643
  • Anahtar Kelimeler: Crohn's disease, ulcerative colitis, cannabinoid receptor-2, polymorphism, CB2 RECEPTOR, ULCERATIVE-COLITIS, CROHNS-DISEASE, PATHOGENESIS, RISK, EPIDEMIOLOGY, POLYMORPHISM, GENETICS, COLON, MICE
  • Marmara Üniversitesi Adresli: Evet

Özet

Background/Aims: The endocannabinoid system can exert beneficial effects on gastrointestinal inflammation, and cannabinoid receptor-2 (CB2) agonists may represent a new therapeutic approach in inflammatory bowel disease (IBD). A functional CB2 Q63R polymorphism (rs35761398) in the CNR2 gene has been shown to affect the immunomodulating properties of the CB2 receptor. We sought to investigate whether the functional CB2 Q63R polymorphism (rs35761398) is associated with IBD susceptibility in a Turkish clinical sample.